Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

The progress of one of the company's clinical programs is being delayed.

Why Selecta Biosciences Stock Is Dropping Today

Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences Inc (NASDAQ: SELB). MMA program includes gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia (MMA).

Selecta Biosciences Stock Is Trading Lower After Gaining Total Rights To MMA Program From AskBio

– Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta –

Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program

WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta's Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021.

Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference

Selecta Biosciences, Inc. is a clinical-stage biopharma company aiming to utilize its quite impressive ImmTOR platform to create increased efficacy biologics with drastically decreased immune response. Selecta's pipeline consists of one clinical-stage enzymatic-therapeutic known as SEL-212 with questionable Phase 2 results and a quickly developing pre-clinical-pipeline of four other therapeutics expected to initiate Phase 1s by 2022.

Selecta: ImmTOR Promises A Therapeutic Revolution, But SEL-212 May Dash Hopes

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2020 Results - Earnings Call Transcript

- First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 -

Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, March 11, 2020, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta's Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference

- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -

Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –

Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy

Novartis

Seelos Therapeutics

Allogene Therapeutics Inc

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based clinical-stage immuno-oncology company.

Why Novartis, Seelos Therapeutics And More Are Moving Today

- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone –

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy

WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta's Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference

Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things.

Selecta: ImmTOR Platform's Potential In Key

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy...

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript

Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.

Selecta's (SELB) Q3 Loss Narrower-Than Expected, Revenues Beat

WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.  (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on November 5, 2020 at 8:30 a.m. ET to discuss its financial results for the third quarter and recent operational highlights.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

What's in Store for Selecta (SELB) This Earnings Season?

Aptinyx Inc

VBI Vaccines

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

3 Top Healthcare Stocks Under $5

Selecta Biosciences (SELB) news for Monday includes insider buying from a Board of Directors member sending SELB stock higher. The post Selecta Biosciences News: SELB Stock Shoots 9% Higher on Insider Buying Buzz appeared first on InvestorPlace.

News for Selecta Biosciences Stock (SELB)